U.S. SECURITIES AND ECHANGE COMMISSION

Washington, D.C. 20549

Form 10-QSB

(Mark One)

[X]  Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange
Act of 1934 for the quarterly period ended March 31, 2000.
[] Transition report pursuant to section 13 or 15(d) of the Securitie Exchange
Act of 1934 for the Transition period from ____ to ____.

Commission File NO. 0-26557

Stemcell Global Research, Inc.
(Exact name of small business issuer as specified in its charter)

Nevada                        					            88-0407473
(State or other jurisdiction		         	(I.R.S Identification No.)
of incorporation or organization)

9978 Washington Street, Camp Dennison, Ohio 45111
(Address of principal executive offices)

Issuer's telephone no. (513) 831-8007

Check whether the issuer:

	(1) filed all reports required to be filed by Section 13 or 15(d) of the
Exchange Act during the past 12 months (or for such shorter period that the
registrant was required to file such reports), and

	(2) has been subject to such filing requirements for the past 90 days

X Yes		No

As of March 31, 2000, there were 1,924,350 shares outstanding of issuer's common
stock.

PART I.  FINANCIAL INFORMATION.

Item 1.  Financial Statements

The information required by this item is attached as an exhibit hereto.

Item 2.  Management's Discussion and Analysis or Plant of Operation.

A.       Management's Plan of Operation

(1) In its initial  operating period ended December 31, 1999,
the  Company  incurred  a net loss of  $210,072.00  for  selling,
general and administrative  expenses related to start-up operations.  It has yet
to receive any revenues  from  operations.  On January 22,  1999,  approximately
twenty  three  (23)  founding  shareholders  purchased  1,651,125  shares of the
Company's  authorized  treasury stock for cash. This original stock offering was
made pursuant to Nevada Revised Statues Chapter 90.490.  Additionally,  in March
of 1999, the Company completed an offering of two hundred seventy three thousand
two hundred and twenty five (273,225)  shares of the Common Stock of the Company
to approximately twenty eight (28) unaffiliated shareholders.  This offering was
made in reliance upon an exemption from the  registration  provisions of Section
4(2) of the Securities  Act of 1993, as amended,  pursuant to Regulation D, Rule
504 of the Act. As of the date of this filing,  the Company has one million nine
hundred twenty four thousand three hundred and fifty  (1,924,350)  shares of its
$0.001 par value common  voting stock issued and  outstanding  which are held by
approximately   fifty  one  (51)   shareholders  of  record.   Management  fully
anticipates  that the proceeds from the sale of all of the Common Shares sold in
the public offering delineated above will be sufficient to provide the Company's
capital needs for the next  approximately  six (6) months to twelve (12) months.
The Company  currently  has no  arrangements  or  commitments  for  accounts and
accounts receivable financing. There can be no assurance that any such financing
can be obtained or, if obtained, that it will be on reasonable terms.

         This is a  development  stage  company.  The Company  believes that its
initial revenues will be primarily  dependent upon the Company's ability to cost
effectively  and efficiently  provide cell therapy  process  technologies to the
medical  profession.  The Company  designates  as its  priorities  for the first
twelve  months of operations as  developing  and  emphasizing  its existing cell
therapy  technologies  to establish  its business in the  biotechnology  market.
Realization  of sales of the  Company's  products,  services  and/or  technology
during  the  fiscal  year  ending  December  31,  2000 is  vital  to its plan of
operations.  There are no  guarantees  that other cell therapy  technologies  or
products  similar to the  Company's  could not enter the market  first;  if they
enter the market first, this would  dramatically  curtail any earnings potential
for the Company.  Additionally,  a superior  competitive  technology  or product
could force the Company out of business.

        As of March 31, 2000,  the Company has yet to generate any revenues.  In
addition,  the Company does not expect to generate  any  revenues  over the next
approximately twelve(12) months. This raises substantial doubt about its ability
to continue as a going concern. The company has received a going concern opinion
on its audited financial statements.

(2) No  engineering,  management or similar report has been prepared or provided
for external use by the Company in connection  with the offer of its  securities
to the public.

(3)  Management  believes that the  Company's  future growth and success will be
largely  dependent on its ability to develop or acquire  products and technology
to meet the evolving needs of its prospective  customers.  The Company  believes
that the long-term  success of its product offerings and technology will require
substantial research and development.

         The Company has yet to incur any  research and  development  costs from
January 20, 1999 (date of inception) through March 31, 2000. However, during the
fiscal and calendar  year ending  December 31, 2000,  the Company plans to incur
research and development  expenses of approximately  $10,000 with respect to its
current and future products and technology.  The cost of such activities are not
expected to be borne by the Company's customers.

(4) The  Company  currently  does  not  expect  to  purchase  or sell any of its
facilities or equipment.

(5)  Management  does not anticipate  any  significant  changes in the number of
employees over the next approximately twelve (12) months.

B.       Segment Data

         As of March 31, 2000,  no sales  revenue  has  been  generated  by the
Company.  Accordingly,  no table  showing  percentage  breakdown  of  revenue by
business segment or product line is included.

PART II.  OTHER INFORMATION

Item 2.  Changes in Securities and Use of Proceeds.

         In April of 1999, the Company  completed a public offering of shares of
common stock of the Company pursuant to Regulation D, Rule 504 of the Securities
Act of 1933, as amended,  whereby it sold 273,225  shares of the Common Stock of
the Company to 28  unaffiliated  shareholders  of record.  The Company  filed an
original Form D with the Securities and Exchange Commission on or about April 5,
1999.  As of March 31, 2000,  the Company has  1,924,350  shares of common stock
issued and outstanding held by 51 shareholders of record.

Signatures

In accordance with the requirements of the Exchange Act, the registrant casued
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

Date:    August 8, 2000
         ------------

By:      /s/ Dr. Garrell Noah
         --------------------
         Dr. Garrell Noah, Chairman of the Board, President and Chief Executive
         Officer
         ----------------------------------------------------------------------

By:      /s/ David Leytze
         --------------------
         David Leytze, Director, Vice President, CFO, Secretary/Treasurer
         ----------------------------------------------------------------